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Purpose: To clinically use the UCSF500, a pancancer, next-generation sequencing
assay in uveal melanoma (UM) and to correlate results with gene expression profiling
(GEP) and predictive factors for metastasis.
Methods: Cohort study. Tumor samples of adult UM patients were analyzed with the
UCSF500 and GEP. Main outcomes were copy number changes in chromosomes 1, 3,
6, and 8 and mutations in GNAQ, GNA11, SF3B1, EIF1AX, BAP1, SRSF2, U2AF1, and
PLCB4. Chromosome 3 loss (a metastasis predictor) was tested for correlation with GEP
class, tumor characteristics (largest basal diameter, thickness, ciliary body involve-
ment, and extraocular extension), and histology (presence of epithelioid cells, closed
loops, and mitotic count).
Results: The 62 patients had a mean age of 59 years (range, 24–89 years).
Chromosome 3 loss was detected in 30 patients and was associated with larger basal
tumor diameter (Wilcoxon rank sum test, P ¼ 0.015), greater thickness (Wilcoxon rank
sum test, P ¼ 0.016) and tumor, node, metastasis stage (Fisher test, P ¼ 0.006),
epithelioid cytology (Fisher test, P , 0.001), BAP1 mutation (Fisher test, P , 0.001),
and chromosome 8q gain (Fisher test, P , 0.001). Class 2 tumors were much more
likely to have chromosome 3 loss than class 1 (odds ratio, 121; P , 0.001). Eleven
patients developed metastatic UM, of which five died during the study. All metastatic
cases had chromosome 3 loss, 8 gain, BAP1 mutation, and class 2 GEP. Five class 1
tumors had chromosome 3 loss.
Conclusions: UCSF500 detects chromosomal copy number changes and missense
mutations that correlate strongly with metastasis predictors, including GEP.
Translational Relevance: Next-generation sequencing of UM should enhance
survival prognostication.
Introduction
Approximately 50% of patients with uveal mela-
noma (UM) develop metastatic disease, which is
almost always fatal. Using multivariable analysis
including patient age, sex, clinical features incorpo-
rated in the tumor, node, metastasis (TNM) staging
system of the American Joint Committee on Cancer,
histopathology, and cytogenetics has become the gold
standard for personalized survival prognostication.1–6
Of all predictive factors, tumor genetic information
remains the most informative, with chromosome 3
loss and BAP1 mutation, as well as class 2 gene
expression profile (GEP) correlating most strongly
with metastatic death.7,8 Chromosome 8 gain also
confers increased mortality risk, with some studies
suggesting that chromosome 3 loss and 8 gain must
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both be present for metastasis to occur.9,10 Chromo-
some 6p gain is associated with a relatively good
prognosis and is rare in tumors with chromosome 3
loss. When chromosome 6p gain coexists with
chromosome 3 loss, survival is better than with
monosomy 3 alone.10,11
More than 85% of UMs show GNAQ or GNA11
mutation, which are mutually exclusive, initiating
oncogenic events, and are, therefore, useful in differen-
tiating UM from other lesions such as choroidal
metastases.12,13 Loss-of-function mutations in the
BAP1 tumor suppressor gene on chromosome 3 are
found in 49% of UM and are strongly correlated with
metastasis.14 Mutations in EIF1AX and SF3B1, which
also tend to occur in a mutually exclusive pattern, are
associated with low and intermediate risk, respective-
ly.15–19 Other less common UM mutations include
SRSF2, U2AF1, PLCB4, and CYSLTR2.18,20,21
CYSLTR2 and PLCB4 occur mutually exclusively with
GNAQ and GNA11 as initiating oncogenic events and
do not influence metastatic behavior. SRSF2 and
U2AF1 appear to function as splicing factors akin to
SF3B1.18
The UCSF500 assay uses hybrid capture enrich-
ment of target DNA to interrogate approximately 500
genes that are frequently mutated in cancers, includ-
ing genes known to be altered in UM. This test also
detects genome-wide chromosomal copy number
changes using the off-target sequencing reads.22 It
has been in clinical use at University of California,
San Francisco (UCSF) since 2013 and is used for a
wide variety of solid and blood cancers.23
The aims of this study were to determine the
clinical use of the UCSF500 assay in UM patients
and to correlate results with known genetic, clinical,
and histopathologic predictors of metastasis. It was
not our intention to identify novel prognostic
markers but rather to reconfirm known correlations
and to determine the clinical utility of the UCSF500
assay for UM. We compared genetic alterations
including prognostically relevant copy number
changes of chromosomes. Chromosome 3 loss (a
metastasis predictor) was correlated with known
genetic aberrations in UM, such as GNAQ, GNA11,
SF3B1, EIF1AX, and BAP1 mutations, GEP class,
and with established clinical and histopathologic
parameters associated with metastatic risk. Results
here are based on our experience using the UCSF500
for UM since 2013, with preliminary findings
presented in 2016.24 To our knowledge, this is the
first study to report both next-generation sequenc-
ing (NGS) and GEP results in a cohort of UM
patients.
Methods
Patients
The 62 patients in this study were recruited
prospectively from the UCSF Ocular Oncology
Service, starting in August of 2013. Patients were
included if treated with proton beam radiotherapy,
plaque brachytherapy, enucleation, or endoresection.
They were excluded if they had received prior
radiotherapy, in case radiotherapy might have influ-
enced genetic testing results. Four patients who were
invited to participate in the study declined to have any
genetic testing of their tumors. This study was
conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines,
under the approval of the UCSF Institutional Review
Board (CC number 14852). Consent for the use of
tissues and data for research was obtained from all
patients.
Clinical Methods
Clinical evaluation included full ophthalmologic
examination and measurement of largest basal tumor
diameter and tumor thickness by B-scan echography
(Eyecubed; Ellex, Adelaide, Australia). Systemic
clinical examination was performed in a routine
manner with abdominal magnetic resonance imaging
performed both with and without contrast at time of
diagnosis and every 6 months thereafter. Postopera-
tively, patients were referred to a medical oncologist
for systemic screening.
Tumors were categorized as involving ciliary body
if they extended anterior to ora serrata. Extraocular
extension was recorded as being present if this was
noted clinically or histopathologically.
Tumor Sampling
Tumors treated by proton beam radiotherapy or
brachytherapy were sampled by transscleral fine-
needle aspiration or transretinal vitrector biopsy25
(25- or 27-gauge). All biopsies were performed prior
to radiation at the time of tantalum marker or plaque
insertion. For eyes undergoing enucleation or endor-
esection, a fresh tumor sample was obtained at the
time of surgery. Tissue samples were provided to the
UCSF Clinical Cancer Genomics Laboratory for
DNA extraction, library preparation, and sequencing
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and to Castle Biosciences (Friendswood, TX) for
GEP.
Histopathologic Examination
The diagnosis of melanoma was confirmed by light
microscopy on sections stained with hematoxylin and
eosin and, if necessary, by Melan A immunohisto-
chemistry. Melanoma cells were categorized as
spindle, epithelioid, or mixed, according to the
modified Callender system.26 For statistical analysis,
tumors were dichotomized as either having no
epithelioid cells (spindle cell morphology) or having
the presence of any epithelioid cells (mixed or
epithelioid morphology).
Genetic Analysis
Next-Generation Sequencing
The UCSF500 assay was performed at the UCSF
Clinical Cancer Genomics Laboratory. This assay
uses solution phase hybrid capture using a custom
bait library (NimblegenSeqCap)27 of 2.8 Mbp of
genomic sequence and includes all exons of approx-
imately 500 cancer-related genes and selected introns
of 40 of these genes. In addition, the assay captures
2,000 unique sequences containing common single
nucleotide polymorphisms within regions devoid of
constitutional copy number variations to assist in
genome-wide copy number and allelic imbalance
analysis.
Barcoded samples were pooled, and captured
libraries were sequenced with a read length of 100
nucleotides from both directions at .500-fold cover-
age on a single lane of an Illumina HiSeq 2500
instrument. Duplicate sequencing reads were removed
computationally to allow for accurate allele frequency
determination and copy number calling. The analysis
was based on the human reference sequence UCSC
build hg19 (NCBI build 37) by using the following
software packages: BWA, 0.7.10-r789; Samtools, 1.1
(using htslib 1.1); Picard tools, 1.97 (1504); GATK,
2014.4-3.3.0-0-ga3711; CNVkit, 0.3.3; Pindel, 0.2.5a7;
SATK, 2013.1-10-gd6fa6c3; Annovar, v2015Mar22;
Freebayes, 0.9.20; and Delly, 0.5.9. Copy number
changes were calculated from on- and off-target reads
using CNVkit.22,28–37
Gene Expression Profiling
Tumor samples were immediately placed after
biopsy or harvesting in provided fixative and packed
with dry ice and sent to Castle Biosciences for gene-
expression profiling, with methods as previously
reported.8
Statistical Analysis
All data analyses were performed using the R
statistical language.38 To test associations between
chromosome 3 loss and other clinical and other
genetic factors, the exact Wilcoxon rank sum test39
and the Fisher’s exact test were used for continuous
and categorical variables, respectively. The odds
ratios and corresponding confidence intervals were
estimated using the fisher.test function.
All categorical variables were dichotomized except
for TNM stage, which was grouped into four levels:
T1, T2, T3, and T4. The Cochrane-Armitage test38
was used to test for trend of TNM stage with
chromosome 3 status. All tests were two-sided, with
P values less than 0.05 regarded as significant.
Kaplan-Meier curves were plotted. The log-rank test
was performed to demonstrate associations between
metastasis-free survival and chromosome 3 loss,
chromosome 8q gain, BAP1 mutation, and GEP
class.
Results
Patient Demographics
Of the 62 patients, 36 were male and 26 were
female. Fifty-three patients were white, 6 were Asian,
and 3 patients were Hispanic (Table 1). The mean age
was 58.56 years (SD, 13.24; range, 24–89 years).
Baseline Study Eye Characteristics
The tumors involved the right eye in 38 patients
and the left eye in 24, with ciliary body involvement in
8 patients, and extraocular extension in 3. The mean
largest basal tumor diameter was 11.94 mm (range,
4.80–20.00) and the median tumor thickness was 5.65
mm (range, 0.69–16.00). The TNM stage was T1 in 18
patients, T2 in 19, T3 in 19, and T4 in 6 (Table 1). All
were N0M0 at diagnosis.
Histopathologic and Genetic Results
The laboratory results are summarized in Figure 1.
The tumors were classified as spindle cell in 25
patients, epithelioid in 15, and mixed in 19. Histology
was inconclusive in three patients, because of pauci-
cellular samples.
Next-Generation Sequencing
Chromosome 3 loss (monosomy 3) was seen in 30
(48%) tumors, with 5 of these showing partial loss of
chromosome 3. Chromosome 8q gain and 6p gain
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were seen in 32 (52%) and 21 (34%) tumors,
respectively. Genome-wide copy chromosomal copy
number changes in two representative cases are shown
in Figure 2. GNAQ and GNA11 mutations were
present in 36 (58%) and 26 (42%) tumors, respectively,
and were mutually exclusive. BAP1 inactivating
mutations were present in 23 (37%) patients. SF3B1
mutations and EIF1AX mutations were detected in 19
(31%) and 8 (13%) tumors, respectively. No tumors
had SRSF2, U2AF1, or PLCB4 mutations.
Gene Expression Profiling
Of the 62 tests performed by Castle Biosciences,
three were categorized as ‘‘technical failure.’’ In five
patients, GEP was not performed. This was because
of transport problems in one case, with two patients
declining Castle testing, and two samples (both from
tumors ,1 mm thick) considered too small for both
types of genetic analysis so that only UCSF500 was
performed.
Treatment
Treatment consisted of proton beam radiotherapy
in 34 patients, enucleation in 18, endoresection in 8,
and plaque brachytherapy in 2 patients (Table 1).
Biopsy Technique
Transretinal biopsy (either with vitrector after
tantalum marker insertion or during endoresection)
was performed in 36 patients and transscleral fine-
needle aspiration in 8, with tumor harvesting after
enucleation in 18 patients.
Correlation of Genetic Alterations With
Predictors of Metastasis
UCSF500 results and clinical and histopathologic
features are presented in Figure 1 and Table 2.
The associations between chromosome 3 loss
(partial or total) and clinical, histopathologic, and
other genetic alterations are presented in Table 3.
Chromosome 3 loss was more frequent in tumors with
larger basal diameter (Wilcoxon rank sum test, P ¼
0.015), greater thickness (P ¼ 0.016), more advanced
TNM stage (P¼0.006), presence of any epithelioid cells
(P , 0.001), BAP1 mutation (P , 0.001), and
chromosome 8q gain (P , 0.001). There was no
statistically significant association found between chro-
mosome 3 loss and the mutational status of GNAQ (P¼
0.200), GNA11 (P¼ 0.200), or SF3B1 (P¼ 0.280). An
inverse association was seen between chromosome 3
loss and chromosome 6p gain (P , 0.001).
Class 2 GEP tumors were much more likely to
have chromosome 3 loss than class 1 GEP tumors
(odds ratio 121, P¼ 6.23 1010).
Association With Metastasis-Free Survival
The median metastasis-free survival time was 27
months (range, 6–60). Metastatic disease developed in
Table 1. Patient Demographics, Tumor Clinical
Features, TNM Stage, and Treatmenta
Patient Information Value, N ¼ 62
Demographics
Mean age (median,
range), years
58.65 (58, 24.00–89.00)
Sex
Male 35 (57)
Female 26 (43)
Race
White 53 (85)
Asian 6 (10)
Hispanic 3 (5)
Tumor clinical features
Affected eye
Right 38 (61)
Left 24 (39)
Location
Choroidal 54 (87)
Ciliary body 3 (5)
Ciliochoroidal 5 (8)
Extraocular extension 3 (5)
TNM stage (all N0M0)
T1 18 (29)
T1a 17
T1b 1
T2 19 (31)
T2a 18
T2b 1
T3 19 (31)
T3a 18
T3b 1
T4 6 (10)
T4b 3
T4c 3
Ophthalmic treatment
Proton beam radiotherapy 34 (55)
Enucleation 18 (29)
Local resection 8 (13)
Plaque brachytherapy 2 (3)
a Values shown are number (nearest %) except where
indicated.
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11 (18%) patients, 5 (8%) of whom died. All patients
with metastases had chromosome 3 loss, chromosome
8q gain, BAP1 mutation, and class 2 GEP. Chromo-
some 3 loss (P ¼ 6.54 3 105) alone and combined
chromosome 3 loss, chromosome 8q gain, and BAP1
mutation (P ¼ 5 3 107) were associated with
metastatic disease. Kaplan-Meier curves (Figure 3)
show that the median survival was 37 months in
patients whose tumors showed chromosome 3 loss
and 35 months in patients whose tumor showed
combined chromosome 3 loss, chromosome 8q gain
and BAP1 mutation (log rank test, P , 0.001).
Discussion
Main Findings
Genetic predictors for metastasis that were detected
with the UCSF500 assay correlated closely with clinical
and histologic risk factors, as well as GEP results. The
UCSF500 assay had a low failure rate, even with small
tumor biopsy samples, providing meaningful genetic
results in all 62 patients tested. Its deployment was
straightforward in routine clinical practice.
Discussion of Methods
Targeted sequencing of DNA can detect multiple
types of genetic alterations, including single nucleo-
tide variants, small insertions/deletions, structural
Figure 1. Tiling plot including clinical, histopathologic, and genetic features for all patients.
Table 2. Tumor Histology and Genetics
Variable Value, N (%)
Histology, N ¼ 59
Spindle cell 25 (42)
Epithelioid 15 (25)
Mixed 19 (32)
Genetics—UCSF500, N ¼ 62
Mutations of relevance
GNAQ 36 (58)
GNA11 26 (42)
SF3B1 19 (31)
EIF1AX 8 (13)
BAP1 23 (37)
Chromosomal aberrations
Chromosome 1 loss 14 (23)
Chromosome 3 loss (any) 30 (48)
Chromosome 3 loss (partial) 5 (8)
Chromosome 6 gain 21 (34)
Chromosome 8 gain 32 (52)
Genetics—gene expression profiling, N ¼ 54
Class 1A 21 (39)
Class 1B 13 (24)
Class 2 20 (36)
Test result of technical failure 3 (37)
Test not done (UCSF500 done only) 5
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rearrangements, and copy number alterations, there-
by providing a richer view of relevant genetic
alterations compared to fluorescence in situ hybrid-
ization and single gene sequencing.2 The method is
quantitative and sensitive enough to detect melanoma
mutations, even in the presence of a considerable
fraction of stromal cells. The low complexity of the
genetic landscape of UMs with highly recurrent
mutations at hotspots of a few genes allows for
accurate quantitation of tumor fractions, providing a
potential advantage over gene expression analyses.
An additional advantage of UCSF500 is its ability
to confirm that the biopsy specimen is of uveal
melanocytic origin, by detecting GNAQ and GNA11
mutations. The richness of molecular data provided
by the UCSF500 may assist in diagnostic accuracy for
other tumors. In a recent study using the UCSF500 in
pediatric neurooncologic patients, the diagnosis of six
tumors (19%) was revised after genomic profiling,
including high-grade glioma to pilocytic astrocytoma,
medulloblastoma to pineoblastoma, ependymoma to
high-grade glioma, and medulloblastoma to central
nervous system high-grade neuroepithelial tumor with
BCOR alteration.23
An advantage of this pancancer assay is also that
genetic mutations of relevance to a variety of cancers
can also be added to the assay as new discoveries are
made. The version of the assay in this study
investigated mutations in GNAQ, GNA11, SF3B1,
EIF1AX, BAP1, and PCLB4. Since the study, U2AF1
and CYSLTR2 have been added. In addition, although
all sequencing was performed on fresh tumor speci-
mens, the UCSF500 assay can also be used to analyze
formalin-fixed, paraffin-embedded tissue,23 although
this was not needed in this study because fresh samples
were available for all patients.
Figure 2. Genome-wide copy number profiles for two representative cases. Shown are the raw log2 ratios of the normalized bin counts
from CNVKit (y-axis) along genomic coordinates (x-axis) with segments obtained by circular binary segmentation (black lines) Top: Copy
number alterations include losses of chromosomes 3, 8p, and 16q and gain of 8q in a UM that also carried a GNAQ p.Q209P and a
truncating BAP1 p.Q4* mutation. Bottom: Copy number gains of 6p and 21 in a tumor with an GNAQ p.Q209L mutation.
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Discussion of NGS Results
The association of genetic alterations, as detected
with NGS, with known predictors of metastasis, listed
in Table 3, are in keeping with the published literature.
Chromosome 3 loss was associated with BAP1
mutation, chromosome 8q gain, largest basal tumor
diameter, tumor thickness, TNM stage, and presence
Figure 3. Kaplan-Meier curves demonstrating time to metastasis. Top: Time to metastasis in patients according to chromosome 3 loss,
detected with the UCSF500 assay. Middle: Time to metastasis in patients with combination of chromosome 3 loss, 8 gain and BAP1
mutation, and time to metastasis with at least one of these three genetic features absent. Bottom: Time to metastasis in patients
according to GEP class (class 1 vs. class 2).
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of epithelioid cells.1,8,9,40,41 As anticipated, chromo-
some 3 loss was inversely associated with chromosome
6p gain.9,15,16,17,18 No PCLB4, SRF2, or U2AF1
mutations were identified. Although CYSLTR2 was
not included in the UCSF500 at the time of the study,
all tumors sequenced had GNAQ and GNA11 muta-
tions. Because CYSLTR2 is mutually exclusive of these
mutations, it is unlikely the lack of the gene in the
assay affected study results.21
As expected, all 11 tumors that metastasized during
the study period had chromosome 3 loss, chromosome
8q gain, BAP1 mutation, and class 2 GEP.9,11,41
Interestingly, the combination of chromosome 3 loss
and chromosome 8 gain has also been shown to confer
increased metastatic risk in oral cancer.42
No significant association between SF3B1 muta-
tion and chromosome 3 loss was seen. There is a lack
of consensus on the prognostic value of the SF3B1
mutation, with some reports indicating lower meta-
static risk15,16,18,43 and another indicating potentially
increased risk of late metastasis.19 Longer-term
follow up will be needed to determine the prognostic
relevance of SF3B1 mutations.
The tissue sample was sufficient for NGS in all 62
tumors. Six of these tumors were less than 2 mm in
thickness, with two less than 1 mm in thickness (i.e.,
0.69 mm and 0.74 mm, respectively). Although the
histopathology was interpreted as inconclusive due to
paucicellular sample in three of these cases, NGS
identified GNAQ or GNA11 mutations in all of these,
providing evidence that the neoplasms were of
melanocytic lineage. In two of these tumors with
inconclusive histology, NGS also confirmed malig-
nancy by identifying chromosome 6p gain in one
tumor and SF3B1 mutation, loss of chromosome 1p,
partial chromosome 3 deletion, and chromosome 8q
gain in the other tumor. The third tumor in which
histology failed was 8.80 mm thick and sampled
transsclerally by fine-needle aspiration biopsy. The
specimen was inadequate for histology probably
because too much was used for genetic studies. In
any case, NGS provided a diagnosis of melanoma by
demonstrating GNA11 and SF3B1 mutations as well
as chromosome 6p gain.
NGS Versus GEP
Notably, there was concordance between GEP
class and NGS sequencing result in all class 2 tumors,
which showed loss of chromosome 3 (P ¼ 63 1010)
and the majority (18 of 21 class 2 tumors) had
chromosome 8 gain. Surprisingly, 4 of 20 (20%) class
Table 3. Association of Clinical and Genetic Variables With Chromosome 3 Lossa
Variable P Value OR 95% CI
Clinical features
Largest basal diameter 0.015 N/A
Thickness 0.016 N/A
TNM stage 0.006 N/A
Epithelioid cells (any) ,0.001 19.07 (4.30–123.20)
Ciliary body involvement 0.131 3.96 (0.63–43.55)
Extraocular extension 0.097 ‘ (0.48–‘)
Genetics—UCSF500
Mutations of relevance
GNAQ 0.198 0.47 (0.15–1.46)
GNA11 0.198 2.12 (0.68–6.79)
SF3B1 0.409 0.56 (0.16–1.91)
EIF1AX 0.054 0.14 (0.003–1.18)
BAP1 ,0.001 ‘ (21.75–‘)
Chromosomal aberrations
Chromosome 1 loss 0.544 1.70 (0.44–6.95)
Chromosome 6 gain ,0.001 0.15 (0.03–0.59)
Chromosome 8 gain ,0.001 35.51 (7.60–244.70)
Genetics—gene expression profiling
Class 2 vs. class 1 ,0.001 120.80 (13.65–5,905.96)
a Significant associations are in bold. OR, odds ratio; CI, confidence interval; N/A, not applicable.
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1A tumors and 1 of 13 (8%) class 1B tumors showed
chromosome 3 loss. Of these class 1 tumors with
chromosome 3 loss, only one patient had true
monosomy 3; the other four patient specimens
demonstrated partial/focal loss of chromosome 3,
sparing the BAP1 locus. Long-term follow up is
needed to determine if partial chromosome 3 loss will
lead to increased metastatic risk in these patients.
Strengths and Weaknesses of Study
Strengths of this study are the prospective data
collection and the large number of patients. The main
weakness is the short follow up, which resulted in few
patients with metastatic disease and prediction of time
to metastasis.
Comparison With Other Studies
The results obtained with NGS in this study are
comparable to those reported with microsatellite
analysis, fluorescence in situ hybridization, GEP,
and other genetic methods used to analyze
UM.1,2,8,9,43,44 A study by Smit et al.45 demonstrated
that an NGS kit developed in Rotterdam, The
Netherlands, specifically for UM showed concordant
results with other methods of genetic analysis.45 This
was done with a bank of carefully selected specimens
and not in routine clinical practice, unlike our study.
The Rotterdam panel analyzed 98 amplicons, which
included 17 amplicons covering highly polymorphic
regions in chromosomes 1 and 8, and 21 amplicons on
chromosome 3, with the remainder covering all exons
on the BAP1 gene and the exons containing known
mutation hotspots on GNAQ, GNA11, EIF1AX, and
SF3B1. In comparison, the UCSF500 assay provides
substantially higher resolution of copy number
changes; it uses hybrid capture rather than polymer-
ase chain reaction amplification for enrichment,
providing a more accurate assessment of copy number
alterations.22 Although the preferred input for
UCSF500 extracted from formalin-fixed paraffin-
embedded tissue is 100 ng to yield a median coverage
of 200 or more unique sequence reads, it can reliably
detect UM typical alterations in unfixed samples with
10 ng of input material or less.
Conclusions
When used in routine clinical practice, the
UCSF500 test successfully identifies known genetic
predictors of metastasis in UM.
The strong concordance between UCSF500 results
and known genetic, clinical, and histopathologic
predictors suggests that the UCSF500 assay is a
useful prognostic test in patients with UM. As with
other genetic methods, the NGS results only indicate
whether the UM is likely to have metastasized;
multivariate analysis that includes anatomic, histo-
pathologic, and genetic predictors is required to
provide more accurate assessment of an individual
patient’s life expectancy.46
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